<DOC>
	<DOC>NCT01125813</DOC>
	<brief_summary>This study will determine the efficacy of human-cl rhFVIII in previously treated patients with severe hemophilia A during prophylactic treatment, treatment of bleeding episodes and in surgical prophylaxis.</brief_summary>
	<brief_title>Efficacy and Safety Study of Human-cl rhFVIII in PTPs With Severe Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Severe hemophilia A ((FVIII:C &lt;= 1%) Male subjects &gt;= 12 years of age Previously treated with FVIII concentrate, at least 50 EDs Immunocompetent (CD4+ count &gt; 200/ul) Negative for anti HIV; if positive, viral load &lt; 200 particles/u; or &lt;400,000 copies/mL Other coagulation disorder than hemophilia A Present of past FVIII inhibitor activity (.= 0.6 BU) Severe liver and kidney disease Receiving of scheduled to receive immunomodulating drugs</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>